+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Allergy Immunotherapy Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 200 Pages
  • July 2024
  • Region: Global
  • Expert Market Research
  • ID: 5797847
The global allergy immunotherapies market size was valued at USD 2.2 billion in 2023. It is expected to grow at a CAGR of 9.60% during the forecast period of 2024-2032, driven by the increasing innovations in the formulation and delivery of allergen immunotherapy (AIT). The market is experiencing robust growth and is expected to reach USD 5.1 billion by 2032.

Global Allergy Immunotherapies Market Analysis

Allergy immunotherapies, also known as allergy shots or subcutaneous immunotherapies (SCIT), are a significant sector in the treatment of allergic disorders. This treatment involves gradually increasing doses of allergens to build tolerance and reduce symptoms.

Market Drivers

  • Growing Prevalence of Allergic Disorders: There is a rising global prevalence of allergies such as rhinitis, asthma, and food allergies. This increase drives demand for effective long-term treatment options, boosting the allergy immunotherapy market.
  • Advancements in Allergen Immunotherapy (AIT): Innovations in the formulation and delivery of AIT, including sublingual immunotherapies (SLIT) and the development of recombinant allergens, are making treatments more effective and convenient, thereby attracting more patients.
  • Increased Awareness and Diagnosis: Enhanced awareness about allergic diseases and their impact, coupled with improved diagnostic techniques, is encouraging more individuals to seek definitive treatments like immunotherapies.
  • Supportive Regulatory Environment: Regulatory approvals for new immunotherapy treatments and streamlined pathways for their approval are positively influencing market growth. For example, the approval of products like Odactra for house dust mite allergies represents significant progress.

Market Challenges

  • High Cost of Treatment: Allergy immunotherapy can be expensive, particularly when long treatment durations are required. This can be a significant barrier, especially in regions without adequate healthcare coverage or insurance.
  • Availability and Accessibility Issues: In many parts of the world, especially in developing regions, access to specialised allergen immunotherapy is limited. This restricts market growth and patient access to these therapies.
  • Side Effects and Safety Concerns: Although generally safe, allergy immunotherapy can have side effects ranging from mild local reactions to severe systemic reactions. These safety concerns can deter some patients from opting for this treatment.
  • Competition from Alternative Treatments: Over-the-counter antihistamines and corticosteroids often provide quicker symptom relief at a lower cost, which can make them more appealing to patients than the long-term commitment of immunotherapy.

Future Opportunities

  • Technological Innovations: Emerging technologies that improve the safety and efficacy of immunotherapies, such as peptide-based therapies which reduce the risk of severe reactions, are expected to drive market growth.
  • Expansion in Emerging Markets: Increasing healthcare spending and infrastructure improvements in emerging markets present significant opportunities for the expansion of allergy immunotherapy.
  • Personalised Medicine: The trend towards personalised medicine can be leveraged in allergy immunotherapy to develop customised treatments that are tailored to individual allergic profiles, improving outcomes and patient satisfaction.
  • Integration with Digital Health Tools: Utilising digital health tools for better patient management and adherence monitoring can enhance the effectiveness of treatment regimes and patient experience.

Global Allergy Immunotherapies Market Trends

The market for allergy immunotherapies is an evolving landscape, shaped by rising allergy prevalence, technological advancements, and shifting healthcare policies. Here are some insightful market trends in this sector:

Growing Prevalence of Allergic Conditions: Increasing urbanisation, changes in lifestyle and dietary habits, and higher pollution levels are contributing to a rise in allergic diseases globally. This increase in allergy prevalence is driving demand for effective long-term treatment solutions, such as allergy immunotherapies.

  • Technological Advancements in Treatment Modalities: There has been significant progress in the development of sublingual immunotherapies (SLIT) and other non-invasive delivery methods. These technologies improve patient compliance and comfort by offering alternatives to traditional subcutaneous immunotherapies (SCIT), which involve injections.
  • Expansion of Allergen Coverage: Research and development efforts are expanding to include a wider range of allergens in immunotherapy treatments, including tree nuts, shellfish, and various types of pollens. This expansion aims to provide tailored and more effective solutions to a broader patient base.
  • Personalised Medicine and Biomarkers: The trend towards personalised medicine is influencing the allergy immunotherapy sector. There is a growing focus on identifying biomarkers that can predict individual responses to immunotherapy, which could lead to more customised and effective treatment plans.
  • Regulatory Support and Product Approvals: Regulatory agencies in various regions are recognising the importance of allergy immunotherapies. There has been an increase in the approval of new therapies and products, which is encouraging investment and innovation in the field.
  • Rising Awareness and Education: Governments and health organisations are increasing efforts to raise awareness about the effectiveness of immunotherapies in managing allergies. This educational push is expected to increase the uptake of these treatments among patients who were previously reliant on symptomatic medications.
  • Partnerships and Collaborations: Companies in the allergy immunotherapy space are increasingly entering into partnerships and collaborations to leverage each other’s strengths in terms of technology, marketing, and geographic reach. This trend is helping to accelerate the development and distribution of new therapies globally.
  • Challenges in Market Access and Reimbursement: Despite the advancements and benefits of allergy immunotherapies, issues related to market access and reimbursement continue to pose challenges. Varying reimbursement policies across countries and the high cost of long-term treatment can limit patient access to these therapies.

Global Allergy Immunotherapies Market Segmentation

Market Breakup by Type of Immunotherapy

  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
The allergy immunotherapy market is segmented into Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT). SCIT, the traditional form, continues to drive substantial market share due to its established efficacy, but faces limitations due to the need for frequent clinic visits. SLIT, on the other hand, is rapidly gaining traction due to its non-invasive nature and ease of administration, enhancing patient compliance. Market growth is propelled by increasing allergy prevalence, demand for patient-friendly treatment modalities, and technological advancements in allergen formulations. SLIT, in particular, is poised to drive market growth in the forecast period, as it offers significant advantages in terms of convenience and potential for home-based treatment, aligning with global trends towards telemedicine and patient-centered care.

Market Breakup by Allergy Type

  • Allergic Rhinitis
  • Asthma
  • Food Allergy
  • Venom Allergy
  • Others
The allergy immunotherapy market is categorised by allergy type, including Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, and Others. Allergic Rhinitis is a major segment, driven by its high prevalence globally and the availability of effective immunotherapy options. Asthma-related immunotherapies are also significant, given the critical need for long-term treatment solutions. Food and Venom allergies are rapidly emerging segments due to rising awareness and the development of targeted treatments. The market is driven by the increasing global incidence of allergies, advancements in specific immunotherapies, and growing patient awareness and healthcare spending. Looking forward, the segments addressing severe and life-threatening allergies, such as food and venom allergies, are expected to witness robust growth, fueled by urgent medical needs and significant investment in research and development. This diverse demand across various allergy types is poised to collectively drive substantial market growth during the forecast period.

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
The allergy immunotherapy market is segmented by distribution channels into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Hospital Pharmacies hold a significant share due to their direct linkage with treatment centers and patient trust in hospital-prescribed therapies. Retail Pharmacies are crucial for accessibility, offering widespread availability of immunotherapies across diverse locations. Online Pharmacies are rapidly growing, fueled by the convenience of home delivery and the increasing digitisation of healthcare services. Market drivers include the rising prevalence of allergies, the convenience of online medicine procurement, and the expansion of healthcare infrastructure. Future growth is especially promising for Online Pharmacies, as e-health services expand and consumer preferences shift towards digital platforms, positioning this segment to significantly drive market growth in the coming years.

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
The allergy immunotherapy market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominates the market, driven by high healthcare spending, advanced medical infrastructure, and a large patient population with allergies. Europe follows closely, supported by strong regulatory frameworks and widespread adoption of both SCIT and SLIT. Asia Pacific is the fastest-growing region, due to rising awareness of allergy treatments, increasing healthcare investments, and a growing middle class. Latin America and the Middle East and Africa are emerging markets, where growth is spurred by improving healthcare systems and increasing access to medical treatments. Overall, the global expansion of the allergy immunotherapy market is fueled by increasing global allergy prevalence, technological advancements in treatment, and a growing emphasis on effective long-term care, with Asia Pacific expected to exhibit the highest growth rate in the forecast period due to rapid healthcare evolution and demographic changes.

Global Allergy Immunotherapies Market Competitive Landscape

The competitive landscape of the allergy immunotherapy market is characterised by the presence of several key players who are actively engaging in various strategic activities to enhance their market position. Leading companies include ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Holding B.V., DBV Technologies, Merck KGaA, Aimmune Therapeutics, NIOX, Anergis S.A., and Allergopharma GmbH & Co. KG. These market participants frequently undertake mergers and acquisitions to expand their geographical reach and product portfolio. Research and development initiatives are common as companies strive to innovate and improve the efficacy and safety of their immunotherapy solutions. New product introductions are regularly made to cater to a broader range of allergies. Additionally, partnerships are formed to leverage collective technological, clinical, and commercial expertise, thereby enhancing the development and distribution of advanced immunotherapeutic products. These activities collectively contribute to a dynamic and competitive market environment.

Key Questions Answered in the Report

  • What is the current and future performance of the global allergy immunotherapies drugs market?
  • What are the main challenges facing the global allergy immunotherapies drugs market?
  • What are the key drivers of the global allergy immunotherapies drugs market?
  • What emerging trends are shaping the future of the allergy immunotherapies drugs market?
  • How is urbanisation influencing the demand for allergy immunotherapies globally?
  • Why do emerging markets present significant opportunities for the expansion of allergy immunotherapy?
  • Why is there an increasing demand for allergy immunotherapies globally?
  • How are biomarkers transforming the customisation of allergy immunotherapy treatments?
  • How are online pharmacies impacting the accessibility of allergy immunotherapies?
  • What strategic activities are key players in the allergy immunotherapy market undertaking?

Key Benefits for Stakeholders

  • The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global allergy immunotherapies market from 2017-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the allergy immunotherapies market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the allergy immunotherapies industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Allergy Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Allergy Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Allergy Epidemiology (2016-2031)
5.3 Europe Allergy Epidemiology (2016-2031)
5.4 Asia-Pacific Allergy Epidemiology (2016-2031)
5.5 Latin America Allergy Epidemiology (2016-2031)
5.6 Middle East & Africa Allergy Epidemiology (2016-2031)
6 Global Allergy Immunotherapy Market Overview
6.1 Global Allergy Immunotherapy Market Historical Value (2017-2023)
6.2 Global Allergy Immunotherapy Market Forecast Value (2024-2032)
7 Global Allergy Immunotherapy Market Landscape
7.1 Global Allergy immunotherapy: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Allergy Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Allergan Type
7.2.3 Analysis by Distribution Channel
8 Allergy Immunotherapy Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Allergy Immunotherapy Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Allergy Immunotherapy Market Segmentation
11.1 Global Allergy Immunotherapy Market by Treatment Type
11.1.1 Market Overview
11.1.2 Subcutaneous Immunotherapy (SCIT)
11.1.3 Specific Immunotherapy (SIT)
11.1.4 Sublingual Immunotherapy (SLIT)
11.1.4.1 Sublingual Drops
11.1.4.2 Sublingual Tablets
11.2 Global Allergy Immunotherapy Market by Allergan Type
11.2.1 Market Overview
11.2.2 Pollen Allergies
11.2.2.1 Grass Pollen
11.2.2.2 Tree Pollen
11.2.2.3 Weed Pollen
11.2.3 Food Allergies
11.2.3.1 Peanut Allergies
11.2.3.2 Tree Nut Allergies
11.2.3.3 Shellfish Allergies
11.2.3.4 Fish Allergies
11.2.3.5 Egg Allergies
11.2.3.6 Milk Allergies
11.2.3.7 Soy Allergies
11.2.3.8 Wheat Allergies
11.2.3.9 Others
11.2.4 Dust Mite Allergies
11.2.5 Mold Allergies
11.2.6 Animal Dander Allergies
11.2.7 Insect Venom Allergies
11.3 Global Allergy Immunotherapy Market by Treatment Channel
11.3.1 Market Overview
11.3.2 Public
11.3.3 Private
11.4 Global Allergy Immunotherapy Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Direct Tenders
11.4.3 Retail Sales
11.4.4 Others
11.5 Global Allergy Immunotherapy Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Allergy Immunotherapy Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Allergy Immunotherapy Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Allergy Immunotherapy Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Allergy Immunotherapy Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Allergy Immunotherapy Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 ALK-Abelló A/S
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Allergy Therapeutics
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Aimmune Therapeutics
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Stallergenes Greer
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Merck Group
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 HAL Allergy Group
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 DBV Technologies
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Biomay AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Anergis SA
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Circassia Pharmaceuticals
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Laboratorios LETI
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 HollisterStier Allergy
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Allergy Immunotherapy Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Alk-Abelló A/S
  • Allergy Therapeutics
  • Aimmune Therapeutics
  • Stallergenes Greer
  • Merck Group
  • Hal Allergy Group
  • Dbv Technologies
  • Biomay AG
  • Anergis Sa
  • Circassia Pharmaceuticals
  • Laboratorios Leti
  • Hollisterstier Allergy

Methodology

Loading
LOADING...

Table Information